CCM
DNTH icon

Catalio Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Catalio Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$47M Sell
560,308
-93,264
-14% -$5.4M 9.82% 1
2025
Q4 		$26.9M Sell
653,572
-14,043
-2% -$544K 4.76% 6
2025
Q3 		$26.3M Sell
667,615
-78,912
-11% -$2.02M 4.86% 7
2025
Q2 		$13.9M Sell
746,527
-16,944
-2% -$318K 2.92% 15
2025
Q1 		$13.8M Hold
763,471
– – 3.37% 12
2024
Q4 		$16.6M Buy
+763,471
New +$19.6M 3.64% 15

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Catalio Capital Management's DNTH Position: Q1 2026 in Review

Catalio Capital Management reduced its Dianthus Therapeutics (DNTH) stake by 14% in Q1 2026, selling an estimated $5.4M and leaving 560,308 shares worth $47M. The position accounts for 9.82% of the portfolio, ranked #1.

Catalio Capital Management first reported a position in DNTH in Q4 2024 and has held it in 6 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Catalio Capital Management held 560,308 shares of Dianthus Therapeutics worth $47M as of Q1 2026.
  • Catalio Capital Management sold 93,264 Dianthus Therapeutics shares in Q1 2026, an estimated $5.4M.
  • Dianthus Therapeutics made up 9.82% of Catalio Capital Management's portfolio in Q1 2026, its #1 holding.
  • Catalio Capital Management first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.